Related Experiment Video

Updated: May 23, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Comparison of late (3-year) registry data outcomes using bare metal versus drug-eluting stents for treating

Abid Assali1, Muthiah Vaduganathan, Hanna Vaknin-Assa

  • 1Department of Cardiology, Rabin Medical Centre, Petah-Tikva, Tel-Aviv University, Tel-Aviv, Israel. aassali@netvision.net.il

The American Journal of Cardiology
|March 24, 2012
PubMed

Insights

Drug-eluting stents (DES) show improved revascularization rates and similar 3-year mortality compared to bare-metal stents (BMS) in ST-segment elevation myocardial infarction (STEMI) patients. However, DES use was linked to a higher risk of late stent thrombosis.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Clinical trials support drug-eluting stents (DES) for ST-segment elevation myocardial infarctions (STEMIs).
  • Limited real-world data exists on the late safety profiles of DES in STEMI patients.
  • Bare-metal stents (BMS) are a common alternative in percutaneous coronary intervention (PCI).

Purpose of the Study:

  • To evaluate the late safety and efficacy of DES versus BMS in STEMI patients undergoing primary PCI.
  • To assess long-term outcomes including mortality, target vessel revascularization, and stent thrombosis.

Main Methods:

  • Prospective registry-based study of 1,569 consecutive STEMI patients.
  • Comparison of 200 patients treated with DES versus 1,369 patients treated with BMS.
  • Primary endpoints: all-cause mortality and target vessel revascularization at 1, 2, and 3 years.

Main Results:

  • All-cause mortality was significantly lower in the DES group at 3 years (4.2% vs 13.5%, p=0.007).
  • Target vessel revascularization was significantly lower in the DES group (10.5% vs 21%, p=0.001), with DES use being an independent predictor.
  • Late definite stent thrombosis (after 1 year) occurred more frequently in the DES group (2.5% vs 0.7%, p=0.05), with DES use as an independent predictor.

Conclusions:

  • DES use in STEMI patients undergoing primary PCI demonstrated improved revascularization rates.
  • No increased 3-year hazard of adverse clinical outcomes was observed with DES compared to BMS.
  • DES use was associated with an increased risk of late stent thrombosis, necessitating careful consideration.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...